A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient’s own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.
Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression.
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.
Understanding how to provide children with an early foundation in school readiness skills is critical, as many states estimate that half of their students, especially those from lower socioeconomic backgrounds, arrive at kindergarten already far behind where they need to be to succeed in school. In order to learn more about how to best prepare young children for school success, the Administration of Children and Families, a part of the U.S. Department of Health and Human Services, has awarded a $2.5 million research grant to the Children’s Learning Institute at The University of Texas Health Science Center at Houston (UTHealth). Ursula Johnson, Ph.D., an assistant professor of pediatrics with the Children’s Learning Institute, said the grant-funded research project will adapt two research-based parent and teacher interventions developed at the Children’s Learning Institute, PALS and BEECH, to examine the benefit to low-income infants’ and toddlers’ language, cognitive and social-
The Global Observatory for Physical Activity (GoPA!), a council of physical activity researchers including Harold Kohl, Ph.D., of the UTHealth School of Public Health, unveiled today baseline data cards for 131 countries across the world. These cards offer a detailed look at physical activity research, policy and surveillance worldwide.
Depression is a significant predictor of five-year survival and recurrence in head and neck cancer patients, according to a new study from The University of Texas MD Anderson Cancer Center.
Many people fall off ladders when putting up holiday lights and severely damage their feet.
Marc Garbey, Ph.D., has joined Houston Methodist as scientific director of the Center for Computational Surgery. He was previously professor in the Department of Computer Science and the Department of Biology and Biochemistry at the University of Houston.
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC).
The optimal treatment approach for most women with breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is complete surgical excision of the implant and surrounding capsule, according to an international study led by researchers at The University of Texas MD Anderson Cancer Center.
The John P. McGovern Foundation has made a transformational $75 million gift to bolster medical training, provide full scholarships and support scientific discovery and innovation at The University of Texas Health Science Center at Houston (UTHealth) and its medical school, UTHealth President Giuseppe N. Colasurdo, M.D., announced today.
Distinguished contributions to understanding p53 tumor suppression in stem cells and breakthrough advances in treating breast cancer have earned two scientists at The University of Texas MD Anderson Cancer Center membership in a notable association of scholars.
A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.
The University of Texas MD Anderson Cancer Center was awarded more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas (CPRIT).
Eric Boerwinkle, Ph.D., a world-renowned genetics researcher and educator, has been appointed dean of The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, effective January 1.
Many people will use caffeine to give them the extra boost they need to get everything done for the holiday season. However, a Houston Methodist internist says the need for more caffeine might be masking some serious sleep problems.
Codiak BioSciences, Inc. announced today the closing of the first portion of a planned $80-plus million Series A and B financing. The company also executed license and sponsored research agreements with The University of Texas MD Anderson Cancer Center in Houston.
Andy Sabin, of East Hampton, N.Y., has committed $30 million — the philanthropist’s largest grant to date — to support research at The University of Texas MD Anderson Cancer Center.
Cetuximab, marketed as Erbitux®, is one of the key therapies for metastatic colorectal cancer. Yet the cancer still returns in some patients, shortening overall survival.
Most of us will seriously overeat between Thanksgiving and New Year's Day. Those people walking around with non-alcoholic fatty liver disease could make the condition a lot worse, opening them up to serious diseases.
Stacey Mitchell of Harris Health System received the Virginia A. Lynch Pioneer Award in Forensic Nursing by the International Association of Forensic Nurses, the highest honor bestowed by the more than 3,000-member association with membership in 27 countries. This award recognizes an individual who has made exceptional contributions to the field of forensic nursing through clinical programs development, scientific achievement, legislation changes or educational activities. Virginia A. Lynch was a founding member of the association and a pioneer in what is today forensic nursing.
The National Cancer Institute awarded Houston Methodist investigator Randa El-Zein, M.B., Ch.B., Ph.D., a $2.8 million, five-year U01 grant to combine mammography features with blood-based biomarkers to more precisely predict a woman’s risk for breast cancer-specific subtypes.
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing gemcitabine’s ability to stop tumor growth.
Former Secretary of State Condoleezza Rice is the honoree of A Conversation With a Living Legend®, benefiting The University of Texas MD Anderson Cancer Center, Tuesday Dec. 1 at the Hilton Anatole in Dallas.
Women put so much stress on themselves to make everything perfect for everything. This unnecessary pressure is not good for their heart health.
Diets high in meat may lead to an increased risk of developing renal cell carcinoma (RCC) through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying.
A team of scientists, led by researchers at The University of Texas MD Anderson Cancer Center and University of California, San Diego Moores Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.
CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.
Diet diversity, as defined by less similarity among the foods people eat, may be linked to lower diet quality and worse metabolic health, according to researchers at The University of Texas Health Science Center at Houston (UTHealth) and the Friedman School of Nutrition Science and Policy at Tufts University.
MD Anderson’s Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign.
Senior physician executive Ryan Walsh, M.D., has been named the chief medical information officer or CMIO of The University of Texas Health Science at Houston (UTHealth).
It’s no surprise that people enjoy warm places like Hawaii but may suffer in hostile locales such as Antarctica. A tumor suppressor gene called PTEN is similar in that it is affected by the microenvironments of certain bodily organs to which it travels.
An analysis of an international, cooperative-led trial of patients with locally advanced non-small cell lung cancer (NSCLC) has shown that those who received intensity modulated radiation therapy (IMRT) had less severe lung toxicity and were able to better tolerate their chemotherapy, compared to patients who received 3–dimensional conformal radiation therapy (3-D CRT).
Immatics US, Inc., a subsidiary of Immatics Biotechnologies GmbH, and The University of Texas Health Science Center at Houston (UTHealth) will collaborate on cellular manufacturing for adoptive cellular therapy (ACT) clinical trials.
Scientists have shown why a drug widely used to treat chemotherapy-induced anemia in ovarian and breast cancer patients also may shorten survival times in some patients by inadvertently stimulating tumor growth.
Children’s Learning Institute researchers at The University of Texas Health Science Center at Houston (UTHealth) were recently awarded federal funding for research covering a variety of education topics ranging from reading comprehension to English-language learners to science, technology, engineering and math (STEM) assessments. A total of $9.8 million in grants among six research projects were given to the Children’s Learning Institute by two sources: the Institute of Education Sciences (IES), a part of the U.S. Department of Education, and the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.
Harris Health System is the only healthcare system in the nation awarded a $150,000 grant to help the U.S. Department of Health and Human Services (HHS) develop and improve ways to share cybersecurity threat information and protect the critical cyber infrastructure of the nation’s public and private healthcare sector.
The Nantz National Alzheimer Center at Houston Methodist Hospital is part of a landmark clinical trial that looks at removing a key protein from the brain to prevent memory loss at least a decade before symptoms are noticed in healthy older adults.
OncoResponse, an immuno-oncology antibody discovery company, has been launched jointly by The University of Texas MD Anderson Cancer Center and Theraclone Sciences.
A career-long fascination with discovering the ins and outs of T cells, our immune system’s tailor-made destroyers of infections and dysfunctional cells, has earned Jim Allison, Ph.D., the American Cancer Society’s 2015 Medal of Honor for Basic Research.
Cancer specialists have long looked at genetic mutations and DNA copy changes to help predict patient survival and drug sensitivity.
Barbara J. Stoll, M.D., an internationally known physician, researcher and educator, has been named dean of The University of Texas Health Science Center at Houston (UTHealth) Medical School.
Researchers at Houston Methodist, along with collaborators at two major Singapore institutions, have developed a lab in a needle device that could provide instant results to routine lab tests, accelerating treatment and diagnosis by days.
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors (NET) of the lung and gastrointestinal tract.
For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.
Dr. Michael O. Gardner is the new executive vice president and administrator of Ambulatory Care Services for Harris Health System, one of the largest public safety-net providers in Texas. Ambulatory Care Services is the system’s integrated network of health centers, specialty facilities, clinics and mobile health units. Gardner, a board-certified physician in Obstetrics and Gynecology, as well as Maternal Fetal Medicine, has 26 years of healthcare experience. He is a licensed physician in Arizona, California, New Mexico, Oklahoma and Texas.
A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.
The National Cancer Institute awarded Houston Methodist and Weill Cornell a multi-million dollar U01 grant to identify non-small cell lung cancer (NSCLC) therapy targets critical to identifying how tumors interact with surrounding cells.
The University of Texas MD Anderson Cancer Center, Cayman Chemical and Fannin Innovation Studio have formed ACF Pharmaceuticals, LLC.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right